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Abstract
Background: The heart responds to myriad stresses by well-described transcriptional responses that involve long-term
changes in gene expression as well as more immediate, transient adaptations. MicroRNAs quantitatively regulate mRNAs
and thus may affect the cardiac transcriptional output and cardiac function. Here we investigate miR-499, a microRNA
embedded within a ventricular-specific myosin heavy chain gene, which is expressed in heart and skeletal muscle.
Methodology/Principal Findings: We assessed miR-499 expression in human tissue to confirm its potential relevance to
human cardiac gene regulation. Using a transgenic mouse model, we found that elevated miR-499 levels caused cellular
hypertrophy and cardiac dysfunction in a dose-dependent manner. Global gene expression profiling revealed altered levels
of the immediate early stress response genes (Egr1, Egr2 and Fos), ß-myosin heavy chain (Myh7), and skeletal muscle actin
(Acta1). We verified the effect of miR-499 on the immediate early response genes by miR-499 gain- and loss-of-function in
vitro. Consistent with a role for miR-499 in blunting the response to cardiac stress, asymptomatic miR-499-expressing mice
had an impaired response to pressure overload and accentuated cardiac dysfunction.
Conclusions: Elevated miR-499 levels affect cardiac gene expression and predispose to cardiac stress-induced dysfunction.
miR-499 may titrate the cardiac response to stress in part by regulating the immediate early gene response.
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Introduction
Heart failure affects over five million individuals in the United
States and is characterized by progressive cardiac dysfunction.
Such cardiomyopathies are characterized by significant changes in
gene expression [1–7], many of which represent adaptive or
maladaptive responses to stress. The immediate early gene
response is activated rapidly upon cardiac stress and in a number
of models of cardiac failure [8]. These genes are rapidly
upregulated in response to environmental stimuli [9–11] and
include the early growth response gene Egr1 and the proto-
oncogene Fos, both of which are involved in the cardiac stress
response [12–14]. The induction of these genes is dependent upon
serum response factor (SRF) and mediates further changes in gene
expression, including regulation of sarcomeric and hypertrophic
genes [15,16].
MicroRNAs are small non-coding RNAs that play an important
role in gene regulation. Each of the over 650 known human
microRNAs likely regulates hundreds of mRNAs and thus has the
potential to affect many biologic processes, although the effect on
rapid transcriptional responses has not been extensively studied.
Some microRNAs are expressed ubiquitously while others display
tissue-specific expression patterns, suggesting unique functions
within tissues. Several microRNAs, including miR-1, miR-133,
miR-206 and miR-208 [17–29], are found in cardiac and/or
skeletal muscle, and each has a potentially distinct regulatory
function. Furthermore, many microRNAs reside within introns of
coding genes, suggesting that their function may have co-evolved
with their host gene [30,31].
In screening for microRNAs enriched in the human heart, we
identified an abundant microRNA, miR-499, which has been the
subject of several recent studies. Global microRNA expression
profiling studies have identified miR-499 in the heart [32–35],
however its function is just beginning to be elucidated. miR-499 is
an evolutionarily conserved muscle-specific microRNA that is
encoded within the intron of myosin heavy chain 7B (Myh7B) and
is highly enriched in the cardiac ventricles. miR-499 plays a role in
myosin gene regulation [36–38], however the functional effects of
altered microRNA dosage may depend on the tissue’s physiologic
state. Furthermore, microRNA levels vary in many cardiac disease
states [30,39–41], and in cardiac samples from individuals with
aortic stenosis leading to pressure-overload and heart failure, miR-
499 levels are altered [40]. In this study we show that elevated
levels of miR-499 in hearts of transgenic mice result in
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19481cardiomyocyte hypertrophy and stress-dependent cardiac dysfunc-
tion. Furthermore, we found miR-499 alters the immediate early
gene response to cardiac stress, which may partially contribute to
the effects of elevated miR-499.
Results
miR-499 is expressed in human heart and skeletal muscle
To identify microRNAs that are enriched in the human heart,
we compared the expression of microRNAs in human fetal heart
and fetal liver using microRNA microarrays. miR-499 was among
the top cardiac-enriched microRNAs (Fig. 1A, Table S1), along
with the well-studied microRNAs, miR-1 and miR-133. miR-499
is distinct from miR-1 and miR-133 in that it is encoded in only
one genomic locus. By genomic sequence alignment, miR-499 is
completely conserved throughout evolution with the exception of a
single nucleotide change in chicken (Fig. 1B). We verified that the
predicted human miR-499 genomic region encoded the micro-
RNA by cloning the pre-miR-499 region, expressing it in cell
culture, and performing Northern blot analysis (Fig. 1C). To
determine the tissue-specificity of miR-499, we surveyed various
human tissue types by Northern blot; miR-499 was detected only
in the heart and in skeletal muscle (Fig. 1D) in agreement with
what has been reported in mice [36,37]. In silico analysis revealed
that miR-499 was located in an intron of the human myosin heavy
chain gene, MYH7B (Fig. 1E), analogous to the arrangement in
Myh7B in mice.
Elevated miR-499 levels are associated with cardiac
hypertrophy in vivo
We hypothesized that miR-499 expression may be playing an
important role in cardiac gene regulation given its expression
pattern, its evolutionary conservation, and its decrement in
pressure-overload conditions such as human aortic stenosis [40].
To determine the consequence of persistent miR-499 expression in
pressure-overload stress, we first generated transgenic mice with
increased levels of miR-499 in the heart by expressing miR-499
under control of the cardiac, alpha-myosin heavy chain (Myh6)
promoter, as it confers increasing postnatal ventricular cardiomy-
ocyte expression [42–44]. We established two transgenic lines,
which varied in degree of miR-499 expression compared to
littermate controls (Fig. 2A). Mice expressing lower levels of miR-
499 (line #17 or TG-17) appeared normal under basal conditions
(n=20). Transgenic mice expressing higher levels of miR-499 (line
#9 or TG-9) developed enlarged hearts (n=16) as demonstrated
Figure 1. Human miR-499 is a conserved muscle-specific microRNA. (A) microRNA expression in human fetal heart compared to liver.
Positive log2 ratio values indicate cardiac enrichment. n=3 independent RNA samples per group, dots with vertical line indicate mean 6 standard
deviation for each microRNA. (B) Alignment of genomic sequences corresponding to mature miR-499 in multiple species. (C) Northern blot with a
miR-499 specific probe with RNA from 293T cells transfected with the genomic sequence surrounding the human or mouse miR-499 locus. Pre-miR
and mature microRNA bands are visible. (D) Mature miR-499 was expressed in human heart and skeletal muscle as detected by Northern blot; U6
small nuclear RNA was probed as a loading control. RNA from miR-499 transfected 293T cells or control vector-transfected cells was used as positive
or negative controls (ctrl). (E) Genomic organization of miR-499 in the myosin heavy chain gene of human MYH7B or mouse Myh7b adapted from the
UCSC genome browser. The conserved intronic location of miR-499 is indicated between exons 20 and 21 in humans and exons 19 and 20 in mouse;
arrows indicate the direction of transcription.
doi:10.1371/journal.pone.0019481.g001
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19481Figure 2. Characterization of hypertrophy phenotype in miR-499 transgenic mice. (A) Cardiac miR-499 expression levels (mean 6 standard
deviation) in transgenic mouse lines compared to littermate controls. (B) Hearts from miR-499 transgenic mice (line #9, TG-9) were larger than those
from littermate controls (6 weeks of age), n=16 mice per group. (C) Coronal optical tomography section of miR-499 TG-9 heart demonstrated
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expressing miR-499 transgenic mice (TG-9) had larger hearts
(Fig. 2C) and increased heart-to-body weight ratios compared to
littermate controls (Fig. 2D), while the brain-to-body weight ratios
were similar. Echocardiography demonstrated decreased fraction-
al shortening in TG-9 mice indicating contractile dysfunction
(Fig. 2E, Table 1).
On histopathological analysis, we found extensive cellular
hypertrophy and patchy interstitial fibrosis in TG-9 hearts
(Fig. 2F) (n=4). To assess the degree of hypertrophy, we
quantified cardiomyocyte cross-sectional area after staining
cardiac sections using wheat germ agglutinin (WGA). TG-9 hearts
displayed a marked increase in cardiomyocyte size indicating
cellular hypertrophy (Fig. 2G and 2H). There was no increase in
TUNEL-positive/alpha-actinin-positive cells in TG-9 mice at 1
week (Fig. 2I and J) or 7 weeks of age, suggesting that
cardiomyocyte apoptosis was not a primary contributor to the
phenotype.
A second line of miR-499 transgenic mice, expressing relatively
lower levels of miR-499 (line #17, TG-17), had hearts that
appeared unremarkable under basal conditions (Fig. 3A). The
ratio of the heart-to-body weights was similar in transgenic and
control mice (Fig. 3B), and echocardiographic evaluation of
cardiac function in TG-17 mice trended lower, although the
results were not statistically significant, at least under basal
conditions (Fig. 3C, Table 1). However, WGA-staining of TG-
17 hearts revealed a mild but significant increase in cardiomyocyte
size (Fig. 3D and E), indicating mild cellular hypertrophy.
miR-499 targeting of Sox6
Given the baseline hypertrophy in miR-499-transgenic mice,
we hypothesized that miR-499 expression may alter genes
important in this cellular program, either directly or indirectly.
Initially, we examined genes predicted to be targets of miR-499
using a targeted approach. From a survey of microRNA target
prediction programs including MiRanda, TargetScan, and
Mirtarget, Sox6 emerged as an attractive candidate, given three
potential miR-499 binding sites and potential roles for Sox6 in
muscle and heart [36–38,45,46]. We verified that Sox6 was an in
vitro target of miR-499 by cloning the Sox6 39-UTR and then
tested for microRNA repression by luciferase assays. We
transfected increasing amounts of miR-499 into 293T cells in
culture and found dose-dependent inhibition of the Sox6 UTR-
luciferase construct, however another cardiac microRNA, miR-
133, had no effect regardless of the dose (Fig. 4A). Surprisingly,
Sox6 protein levels were not diminished in transgenic mice,
however the myosin heavy chain classically involved in
hypertrophy, ß-myosin heavy chain (ß-MyHC), was markedly
increased (Fig. 4B). This was accompanied by an increase in the
corresponding Myh7 (ß-MyHC) transcript, while Sox6 mRNA
was unaltered, similar to its protein levels (Fig. 4C).
A distinctive pattern of cardiac gene regulation mediated
by miR-499
We investigated miR-499-dependent changes in cardiac gene
expression by comparing global gene expression in miR-499-
transgenic mice and littermate controls. To avoid changes
secondary to heart failure, we used the miR-499 transgenic line
(TG-17) that did not display overt cardiac dysfunction. RNA was
prepared from the ventricles of postnatal day 17 miR-499
transgenic mice or littermate controls, and gene expression was
compared by microarray analysis (Fig. 5A). When we analyzed for
differentially expressed genes, 0.03% of the transcripts (nine
transcripts of the 28,853 interrogated) were dysregulated when we
used a stringent cut-off (P value,0.05, Benjamini-Hochberg
correction for false-discovery rate), whereas a less stringent cut-
off demonstrated that 0.5% of the transcripts (172 transcripts of
the 28,853 interrogated) were significantly altered (Bayes log odds
of differential expression B.0). The average fold change was 1.43
for upregulated genes and 21.37 for downregulated genes with a
range of 2.51 to 22.53 fold. miR-499 levels were increased 12.6-
fold, in agreement with our microRNA qPCR results.
chamber enlargement compared to control. (D) Heart-to-body weight ratios of miR-499 transgenic (TG-9) or littermate control (WT) mice. Brain-to-
body weight ratios are also shown. Data from individual mice are plotted as dots with the mean indicated by a horizontal bar. *P=0.0002. (E)
Fractional shortening measured by echocardiography of WT or TG-9 mice. *P=0.00047, n=8 mice for WT, 4 for TG. (F) Histological section of heart
revealing area of fibrosis in TG-9 hearts compared to WT as shown by Masson trichrome staining in myocardium (upper panels) or beneath the
endocardial surface (lower panels); magnification 4006. (G) Quantification of cardiomyocyte size from TG-9 mice compared to WT mice (RV, right
ventricle, and LV, left ventricle, both *P,0.05; box plots depicts size distribution of over 300 cells per heart in each of two mice per group). (H) Wheat
germ agglutinin (WGA) staining; magnification 2006. (I) TG-9 and WT heart demonstrated similar levels of apoptosis, n=3 mice per group;
representative stained histologic section (J) demonstrated the alpha-actinin staining (red) and DAPI-stained nuclei (blue) overlaid with TUNEL-positive
nuclei (green, right panel).
doi:10.1371/journal.pone.0019481.g002
Table 1. Echo Assessment of miR-499 Transgenic Mice.
WT TG-9 P value WT TG-17 P value WT{ TG-17{ P value WT TAB{ TG-17 TAB{ P value
%FS 38.6361.95 23.8869.06 0.00047* 40.6760.88 37.4264.82 0.31 39.764.16 36.364.13 0.34 30.962.29 19.964.10 0.00079*
LVEDD 3.8560.18 4.1861.06 0.37 3.7160.23 3.8360.09 0.38 3.7960.41 3.8160.11 0.95 3.7460.08 4.1860.27 0.0095*
LVESD 2.3760.17 3.2461.21 0.047* 2.2060.14 2.4060.24 0.26 2.2960.37 2.4360.21 0.57 2.5860.09 3.3560.38 0.0023*
LVPWd 0.7260.05 0.7660.11 0.43 0.7260.08 0.6860.03 0.42 0.7960.07 0.8160.04 0.66 1.0860.03 1.0560.04 0.26
LVPWs 1.2060.07 1.0060.15 0.0054* 1.1960.06 1.1260.08 0.25 1.3160.06 1.2660.09 0.44 1.4660.09 1.2360.11 0.0078*
Measurements of left ventricle (LV) in mm 6 standard deviation, LVEDD, end-diastolic dimension; LVESD, end-systolic dimension; LVPWd, posterior wall diastole; LVPWs,
posterior wall systole. n=8 for WT, 4 for TG-9, 3–5 for TG-17. P values calculated using student’s T-test.
{Second assessment 5 weeks later.
{TAB 3.5 mo after thoracic aortic banding.
*P,0.05.
doi:10.1371/journal.pone.0019481.t001
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myosin heavy chain (Myh7), and alpha 1 skeletal muscle actin (Acta1),
genes that are known to be upregulated in hypertrophy, were
increased 2.0, 1.9, and 1.6 fold, respectively (Fig. 5B). Sox6, which
was a target for miR-499 in luciferase assays, was not altered in
transgenic mice (1.0 fold, not significant). We noted that the most
downregulated transcripts were the immediate early response
genes, early growth response 1 (Egr1)( 22.5 fold, the most
downregulated transcript in the entire array) and FBJ osteoscarcoma
oncogene (Fos)( 21.9 fold, the second most downregulated transcript)
(Fig. 5C). Egr2, an immediate early gene with an unknown role in
the heart, was diminished 21.6 fold, and was also among the ten
most downregulated transcripts. As the immediate early genes may
be involved in the response to stress, we validated the reduced
Egr1, Egr2, and Fos levels using qPCR, which further suggested
dysregulation (Fig. 5D).
The Immediate Early Gene Response is Altered by
miR-499 Levels
We reasoned that the immediate early response genes may be
playing a role in the hypertrophic phenotype for several reasons: 1)
the immediate early response genes are rapidly altered in response
to cardiac stress [8,47,48]; 2) perturbation of the immediate early
response alters cardiac hypertrophy [49,50]; and 3) immediate
early genes are typically SRF-dependent, and the cardiac
abnormalities in the miR-499 transgenic partially resembled that
of mice where SRF was temporally deleted [51]. First, to examine
the miR-499:immediate early gene relationship independent of the
potential complexity of the in vivo transgenic system, we tested
whether the immediate early gene response was altered using
cultured cells where miR-499 levels were manipulated. We used
an antisense morpholino to inhibit miR-499 generation in the
ventricular cardiomyocyte line, H9c2. Knockdown of miR-499
levels led to an increase in Egr1 and Fos levels 30 min following
immediate early gene response activation by serum (Fig. 6A),
however the effect was temporally limited, as it resolved by
60 min. Conversely, introduction of miR-499 mimic lowered Egr1
levels in cell culture after serum stimulation (Fig. 6B). There was
no significant effect on Fos in this setting. These data are consistent
with a role for miR-499 in regulating the immediate early gene
response.
We next investigated whether elevated miR-499 levels affected
the epidermal growth factor (EGF)-induced immediate early gene
response in vivo [52]. miR-499-transgenic mice (TG-17) displayed a
blunted activation of Egr1 in response to systemic administration
of EGF (Fig. 6C). Activation of Fos was not different in the miR-
499 transgenic mice, similar to what we observed in cultured cells.
These data suggested that miR-499 levels negatively regulate the
stress-induced activation of Egr1 and this may be important in the
cardiac response to stress and in hypertrophy.
We assessed whether serum response factor (SRF), which is
upstream of the immediate early genes, was altered in the miR-499
transgenics. When we compared SRF protein levels in WT and
TG mice, there was no difference (Fig. 6D), suggesting that the
immediate early genes are regulated by miR-499 independent of
SRF levels. To test whether miR-499 directly or indirectly
Figure 3. Modest levels of miR-499 expression results in mild hypertrophy. (A) Gross appearance of hearts from miR-499 transgenic mice
(line #17, TG-17) and littermate controls (WT) was similar. (B) Heart-to-body weight ratios in TG-17 and WT, n=4–6 mice per group. (C) Fractional
shortening of WT or TG-17 mice by echocardiography. (D) WGA staining of histological sections of hearts from TG-17 and WT mice; magnification
2006. (E) Quantification of cardiomyocyte size revealed an increase in TG-17 (RV and LV both *P,0.05).
doi:10.1371/journal.pone.0019481.g003
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immediate early response genes and placed each downstream of
luciferase and tested these in H9c2 and 293T cells. miR-499 did
not repress luciferase constructs with the Egr1, Egr2, or Fos UTRs
(Fig. 6E), whereas miR-499 repressed constructs containing the
Sox6 39UTR. Since the 39 UTRs of Egr1, Egr2, and Fos were
insufficient to mediate miR-499 repression, we suspect they are
affected by miR-499 in a yet unknown manner that is not
dependent on altered SRF levels.
miR-499 Expressing Mice Are Predisposed to Stress-
Induced Cardiac Dysfunction
Given the effect of miR-499 levels on the immediate early gene
response, which is known to be involved in cardiac stress and
hypertrophy [12–14], we hypothesized that increased miR-499
levels may predispose to stress-induced cardiac dysfunction. We
therefore tested whether the TG-17 miR-499-transgenic mice,
which had normal function at baseline, were predisposed to
increased cardiac dysfunction upon cardiac pressure overload. We
used the well-characterized model of thoracic aortic banding
(TAB) to induce pressure overload in miR-499 transgenic (TG-17)
or control mice and monitored cardiac function over 12 weeks.
The banded transgenic hearts demonstrated accentuated cardiac
enlargement (Fig. 7A) and a marked increase in heart weight to
body weight ratio (Fig. 7B) compared to banded WT controls.
After TAB, the miR-499 transgenic mice displayed more severe
contractile dysfunction as indicated by the decline in fractional
shortening compared to control mice (Fig. 7C, Table 1) that
underwent the same degree of TAB (peak aortic pressure gradient:
WT 49610 mmHg, TG 4369 mmHg, p=0.251). Interestingly,
the cardiomyocyte size was not higher in the LV, but was slightly
increased in the RV of transgenic mice (Fig. 7D and 7E), similar
to TG-9 mice. Overall, these results suggest elevated miR-499
levels predispose the heart to cardiac dysfunction.
To determine the dose-responsiveness of miR-499 sensitive
genes, we analyzed gene expression in the higher miR-499
expressing TG-9 line at 17 days of age. Thirty-two common
transcripts were altered in both TG-17 and TG-9, and thirty of
Figure 4. miR-499 targeting of Sox6. (A) The 39UTR of Sox6 was placed downstream of a luciferase reporter construct and tested for repression
by miR-499 in 293T cells. Sox6 39UTR-mediated repression increased as amounts of miR-499 was increased; this was not observed with miR-133 or
when the UTR orientation was reversed, n=3–4 transfections per condition, *P,0.05. (B) Western blots indicate protein levels in TG-9 or WT hearts
using antibodies against Sox6, ß-myosin heavy chain (ß-MyHC), or Gapdh. Results are representative of three hearts each. (C) Cardiac expression of ß-
myosin heavy chain (ß-MyHC) or Sox6 mRNA transcripts in TG lines and WT mice by qPCR, n=3.
doi:10.1371/journal.pone.0019481.g004
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None of the genes were predicted by Targetscan. Importantly,
pathway analysis revealed enrichment for the GO terms
sarcomere (P=0.0074), contractile fiber part (P=0.0085), myofi-
bril (P=0.0095), and contractile fiber (P=0.010), further high-
lighting the potential role of miR-499 in regulating sarcomeric
function in the heart.
Discussion
In this study, we found that elevated levels of miR-499 in the
heart can lead to cardiomyocyte hypertrophy and cardiomyopathy
in a dose-dependent manner. High levels of miR-499 led to
spontaneous cardiac contractile dysfunction, while more modest
levels of transgenic expression conferred susceptibility to pressure-
induced dysfunction.
Our studies support an association between elevated cardiac
miR-499 levels and cardiac dysfunction, particularly in the setting
of pressure overload. Interestingly, in a study that analyzed
microRNAs in human aortic valve stenosis, miR-499 levels were
decreased [40], and it is possible that this decrement may regulate
cardiac gene expression changes that are important in the
physiologic response to cardiac pressure load. We suspect the
failure of normal miR-499 down-regulation in our transgenic mice
disrupted the normal response to cardiac pressure stress; similar
theories have recently been put forward for cardiac transgenic
mice expressing miR-133a [53]. Interestingly, a recent study [39]
reported that miR-499 levels increase in human cardiac failure,
and the findings in our transgenic mouse model may support a
detrimental role for elevated miR-499 levels.
We identified a discrete set of altered transcripts in unmanip-
ulated, normally functioning, miR-499 transgenic hearts, including
natriuretic peptide precursor type B (Nppb), ß-MyHC (Myh7) and
alpha 1 skeletal muscle actin (Acta1). This suggests gene expression
changes due to miR-499 that favor hypertrophy. These changes
were confirmed in the second transgenic line. The limited
magnitude of transcript changes by miR-499 suggests that the
hypertrophic phenotype observed was not due to gross gene
expression disruption. Although the Sox6 39UTR could be
targeted by miR-499, as we and others have demonstrated [36–
38,46], Sox6 levels were not altered in the transgenic mice,
suggesting that Sox6 was not targeted by increased miR-499 levels
in vivo, or that additional compensatory mechanisms may be
involved in vivo. It is possible that targets seen in luciferase assays
may not necessarily translate into targeting in vivo.
We present several lines of evidence that demonstrate that miR-
499 levels fundamentally alter the immediate early gene response,
which is known to be important in the cardiac stress response.
First, Egr1 and Fos were the most diminished transcripts in TG-17
miR-499-altered hearts, suggesting a robust alteration in the
immediate early gene expression program, while in TG-9 Egr1
was also altered (although Fos was not significantly changed).
Second, inhibition of miR-499 in culture led to increases in
induced Egr1 and Fos levels, which demonstrates that this
regulation is present even outside of the context of the cardiac
transgene. Pressure-induced stress, which is known to invoke the
Figure 5. Altered cardiac transcripts from global analysis of miR-499 TG hearts. (A) Expression microarray results depicting average log2
intensity of gene expression from post-natal day 17 WT hearts (x-axis) versus TG-17 hearts (y-axis). Each dot represents a single transcript from three
miR-499 transgenic mice and three littermate controls. The dot indicated in red (arrow) represents miR-499 expression. (B) and (C) Gene expression
alterations in miR-499 mice (top ten up- and downregulated genes). Egr1 and Fos were the most downregulated transcripts. Full expression data
have been deposited in NCBI GEO. (D) qPCR validation of microarray results regarding the immediate early response gene transcripts Egr1, Egr2, and
Fos. *P,0.05, n=3 hearts per group with samples assessed in triplicate. Bars indicate mean with 95% confidence interval.
doi:10.1371/journal.pone.0019481.g005
miR-499 Stress Response
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19481immediate early gene response, dramatically altered cardiac
function in transgenic mouse hearts. We therefore hypothesize
that miR-499 alters the cardiac response to stress in part by
modulating the immediate early gene response.
The connection between miR-499 and the immediate early
gene response is important since activation of this pathway is
thought to precede further transcriptional responses to stress.
Similar to TG-17 mice expressing miR-499, mice deficient in Egr1
are normal at baseline, but have an impaired response to cardiac
stress [49], as do transgenic mice expressing the Egr1-repressor,
Nab1 [50]. Interestingly, mice lacking the cardiac-specific
microRNA miR-208a have decreased amounts of miR-499
Figure 6. miR-499 blunts the induction of the immediate early response genes. (A) Egr1 and Fos mRNA levels by qPCR relative to Gapdh in
the ventricular cell line H9c2, upon introduction of a morpholino (MO) that blocks miR-499 generation or a control MO. (B) Egr1 and Fos mRNA levels
by qPCR in H9c2 cells after the introduction of miR-499 or control mimic. The x-axis in (A) and (B) indicates the time after serum stimulation to
activate the immediate early gene response; n=3 per group. *P,0.05. (C) Egr1 or Fos mRNA levels in miR-499 TG-17 or WT hearts as assessed by
qPCR 1.5 hours after in vivo stimulation with epidermal growth factor (EGF). Bars indicate mean 6 standard deviation; n.3 per group. *P,0.05. (D)
Western blot indicates protein levels in TG-9 or WT hearts using SRF antibodies with Gapdh as loading control. Results are representative of three
hearts each. (E) The 39 UTR of Sox6, Egr1, Egr2, or Fos was placed downstream of a luciferase reporter construct and tested for repression by miR-499
in culture. Sox6 39UTR-mediated repression by miR-499 was evident, however Egr1, Egr2, and Fos 39UTRs were not repressed by miR-499 (n=3 per
condition, *P,0.05).
doi:10.1371/journal.pone.0019481.g006
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208a mutant mice revealed elevated levels of Egr1, Egr2, and Fos
in the heart, suggesting a potential relationship between miR-499
and miR-208 in regulation of the immediate early gene response
to cardiac stress. The observation that miR-499 transgenic mice
develop or are predisposed to cardiac dysfunction may reflect the
fact that the immediate early response genes hold a key position in
the hierarchy of the cardiac transcriptional response to stress. It
will be interesting to determine if levels of this non-coding RNA
affect the progression of disease in the setting of pressure overload,
such as in hypertension or aortic valve disease.
Materials and Methods
Ethics Statement
Care and handling of all experimental animals used in this study
were in accordance with the University of California San
Francisco’s Institutional Animal Care and Use Committee policies
and approved under protocol #AN080001.
MicroRNA detection by Northern blotting
Total RNA (12 mcg) was separated on 12% polyacrylamide/
urea gels and transferred to nitrocellulose membranes. Mem-
branes were probed with
32P-labelled locked nucleic acid probe
(Exiqon) or DNA oligonucleotide probe complementary to mature
miR-499 or to U6. We transfected 293T cells (ATCC) with miR-
499-expression construct or vector alone for RNA for positive and
negative controls. Signals were detected by phosphoimaging.
MicroRNA and messenger RNA detection by PCR
RNA samples were reverse transcribed for microRNA detection
with microRNA-specific primers (Applied Biosystems) or for
mRNAs with oligo-dT (Invitrogen). miR-499 levels and mRNAs
were quantified using RNA from transgenic mouse hearts and
littermate controls. Quantitative real-time PCR (qPCR) was
performed in an ABI HT7900 with Taqman primers (Applied
Biosystems). Taqman primers used: miR-499 (001352), miR-16
(000391), ß-myosin heavy chain (Myh7, Mm00600555_m1), Sox6
(Mm01274768_m1), Egr1 (Mm00656724_m1), Egr2 (Mm00456650_
m1), Fos (Mm01302932_g1).
MicroRNA genomic cloning
We amplified fragments containing miR-499 from genomic
DNA using high-fidelity PCR (PlatinumTaq, Invitrogen) and
directional cloning into pcDNA3.1-TOPO (Invitrogen) for
expression studies in cell culture. The UCSC genome browser
and Sanger miRBase were used to analyze cloned products, to
assess microRNA conservation, and for primer design.
MicroRNA target assays
We surveyed mutliple bioinformatics prediction programs that
predict potential microRNA targets. MiRanda, TargetScan, and
Figure 7. miR-499 elevation predisposes to stress-induced cardiac dysfunction in vivo. (A) Following thoracic aortic banding (TAB), TG-17
hearts were slightly larger compared to banded WT hearts, and (B) the heart-to-body weight ratio was increased to a greater degree in TG-17
compared to similarly banded WT controls (n=4–5 per group, *P,0.05). (C) Fractional shortening of WT and TG-17 hearts by echocardiography,
*P=0.00079. (D) WGA staining and quantification revealed increased size of cardiomyocytes following TAB. *P,0.05.
doi:10.1371/journal.pone.0019481.g007
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untranslated regions (UTRs) of Sox6, Egr1, Egr2, or Fos were
cloned into pcR2.1-TOPO (Invitrogen) and subcloned down-
stream of the luciferase coding sequence in pMIR-REPORT
(Ambion). For microRNA target assays, we transfected cells with
microRNA expression vector (50, 100, and 250 ng) and luciferase
construct containing the target sequence of interest. Briefly, we
expressed microRNAs in H9c2 or 293T cells with expression
plasmids, equalized the total amount of DNA transfected, and
expressed the luciferase construct with the 39 UTR of interest
(Lipofectamine 2000, Invitrogen). We also tested whether
repression was lost when we transfected the reversed 39UTR
sequence construct with our miR-499 vector (250 ng). Renilla
luciferase-expressing plasmid (pRL-CMV, Promega) was used to
normalize transfection efficiency.
Transgenic mice
To express miR-499 in vivo, we amplified DNA surrounding the
mouse pre-miR-499 region and cloned the 574-bp fragment into
the alpha-myosin heavy chain promoter vector using the following
primers and SalI linkers: 59-CGT GTC GAC CAA GTC TGG
GGT GAA AGA GAA G-39 (forward), 59-TGT GTC GAC GGT
CAT GAG CTT GTT GAG GTT C-39 (reverse) and injected
into one-cell FVB/NCrl embryos before implantation in pseudo-
pregnant females. Phenotyping was performed by echocardiogra-
phy (Vevo 770, VisualSonics) with standard measurement
techniques (reviewed in [57]). Echocardiography was performed
using anesthesia with isofluorane and with continuous monitoring
of mice to ensure the heart rate was kept constant. Thoracic aortic
banding was performed as described [58] with slight modifications.
Briefly, the aorta was exposed through a mediastinal approach,
and suture was tied around a 27-gauge needle placed adjacent to
the aorta. Echocardiography confirmed aortic constriction by peak
velocity measurement. For analysis of transgenic hearts, hearts
were harvested in PBS containing 25 mM KCl and optical
projection tomography was performed for virtual sectioning [59].
Histologic analysis was performed using Masson Trichrome
staining, DAPI, alpha-actinin staining (clone EA-53, Sigma), and
wheat germ agglutinin staining on corresponding coronal sections
followed by quantification of cardiomyocyte cross-sectional area
by measuring the cell diameter with visible nuclei in over 300 cells.
Cell death was assessed by quantification using alpha actinin-
staining combined with tunel analysis (Roche) at different ages.
For analysis of the immediate early gene response in vivo,
recombinant epidermal growth factor (30 mcg, Invitrogen) or
vehicle (normal saline) was injected intraperitoneally into control
or transgenic mice, and hearts were collected after 1.5 hours for
analysis of immediate early gene expression.
Western blotting
Protein lysates were run on SDS-PAGE gels, transferred to
PVDF membranes, and probed with antibodies to Sox6 (ab12054,
Abcam), slow myosin (clone NOQ7.5.4D, Sigma), SRF (sc-335,
Santa Cruz), or Gapdh (Santa Cruz).
Gene expression analysis
Data have been deposited in The National Center for
Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) series accession num-
ber GSE21104 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=nrqpfuaaqeacsxo&acc=GSE21104). Total RNA was
isolated from ventricular tissue from three miR-499-transgenic
mice (line #17, TG-17) and three littermate controls at postnatal
day 17. Gene expression was assessed using Mouse Gene 1.0 ST
Array as recommended by the manufacturer (Affymetrix).
Differentially expressed genes were identified using the limma
package. Adjustment for multiple testing was performed as
described in the text. Further validation was performed using
qPCR as described above. Human heart and liver RNA samples
(Virogen), gestational age 6–8 weeks, were labeled and run for
microRNA expression as described by the manufacturer (Exiqon).
Gene ontology analysis was performed using DAVID Bioinfor-
matics Resources 6.7 [60,61].
MicroRNA modulation in cell culture
To modulate microRNA levels, miR-499 mimic or control
mimic (Dharmacon) or a morpholino directed against the miR-
499 precursor or a scrambled control morpholino (GeneTools) was
electroporated (Amaxa) into H9c2 and allowed to recover
overnight. After serum starvation in 1% fetal bovine serum,
10% serum was applied for designated times and RNA collected
for RT-PCR analysis. Sequence of morpholino directed against
the miR-499 precursor 59-ATG CAG AGG AGC TAA ACA
TCA CTG C-39 or a scrambled control morpholino 59-GAT
TGC GAA GAG TCT CAC AAG ACC A-39.
RNA isolation
Total RNA was isolated using guanidine thiocyanate and
phenol (Molecular Research Center, Inc.) and following manu-
facturer’s instructions for chloroform extraction, isopropanol
precipitation, and 75% ethanol washing. For tissue RNA
extraction, tissues were processed using a bead homogenizer
(WisBiomed).
Primer sequences
Genomic amplification primers for human miR-499: 59-CAC
CCA AGT CTG GGG TGA AAG AGA AG-39 (forward) and 59-
GGT CAT CAG CTT GTT GAG GTT C-39 (reverse). 39UTR
sequence primers: Egr1 59-GGC AGG AAA GAC ATA AAA
GCA C-39 (forward) and 59-ACA TAT CCC ATG GGC AAT
AGA G-39 (reverse), Egr2 59-AAC ACT ACC ACC CTT CCC
TGT T-39 (forward) and 59-AGC CAT CCA TTA TCT GAA
CTC C-39 (reverse), Fos 59-TGG TGC ATT ACA GAG AGG
AGA A-39 (forward) and 59-TGG AAC AAT AAG CAA ACA
ATG C-39 (reverse), Sox6 59-CTC ACT AGT TGG CTC CAC
AAT ACA TCA GC-39 (forward) and 59-CTC AAG CTT CCA
AGT GAC AAA ATG GCT CA-39 (reverse).
Supporting Information
Table S1 Enrichment of microRNAs in human heart versus
liver. Log ratio for each microRNA and standard deviation are
shown. Positive ratios indicate enrichment in heart compared to
the liver.
(DOC)
Table S2 Common genes altered in miR-499 transgenic lines,
TG-17 and TG-9. For each gene, the gene symbol, genomic
location, log ratios and fold change of TG versus WT are shown.
(XLS)
Author Contributions
Conceived and designed the experiments: JS. Performed the experiments:
JS YH JG. Analyzed the data: JS DS. Wrote the paper: JS DS.
miR-499 Stress Response
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19481References
1. Liew CC, Dzau VJ (2004) Molecular genetics and genomics of heart failure. Nat
Rev Genet 5: 811–825.
2. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349: 60–72.
3. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, et al. (2002)
Myocardial gene expression in dilated cardiomyopathy treated with beta-
blocking agents. N Engl J Med 346: 1357–1365.
4. Kaab S, Barth AS, Margerie D, Dugas M, Gebauer M, et al. (2004) Global gene
expression in human myocardium-oligonucleotide microarray analysis of
regional diversity and transcriptional regulation in heart failure. J Mol Med
82: 308–316.
5. Hwang JJ, Allen PD, Tseng GC, Lam CW, Fananapazir L, et al. (2002)
Microarray gene expression profiles in dilated and hypertrophic cardiomyo-
pathic end-stage heart failure. Physiol Genomics 10: 31–44.
6. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, et al. (2006)
Identification of a common gene expression signature in dilated cardiomyopathy
across independent microarray studies. J Am Coll Cardiol 48: 1610–1617.
7. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, et al. (2010)
Differential DNA methylation correlates with differential expression of
angiogenic factors in human heart failure. PLoS One 5: e8564.
8. Izumo S, Nadal-Ginard B, Mahdavi V (1988) Protooncogene induction and
reprogramming of cardiac gene expression produced by pressure overload. Proc
Natl Acad Sci U S A 85: 339–343.
9. Sassone-Corsi P, Verma IM (1987) Modulation of c-fos gene transcription by
negative and positive cellular factors. Nature 326: 507–510.
10. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, et al.
(1988) A zinc finger-encoding gene coregulated with c-fos during growth and
differentiation, and after cellular depolarization. Cell 53: 37–43.
11. Chavrier P, Zerial M, Lemaire P, Almendral J, Bravo R, et al. (1988) A gene
encoding a protein with zinc fingers is activated during G0/G1 transition in
cultured cells. Embo J 7: 29–35.
12. Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, et al. (1990)
Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem
265: 3595–3598.
13. Iwaki K, Sukhatme VP, Shubeita HE, Chien KR (1990) Alpha- and beta-
adrenergic stimulation induces distinct patterns of immediate early gene
expression in neonatal rat myocardial cells. fos/jun expression is associated
with sarcomere assembly; Egr-1 induction is primarily an alpha 1-mediated
response. J Biol Chem 265: 13809–13817.
14. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC,
et al. (1990) Endothelin induction of inositol phospholipid hydrolysis, sarcomere
assembly, and cardiac gene expression in ventricular myocytes. A paracrine
mechanism for myocardial cell hypertrophy. J Biol Chem 265: 20555–20562.
15. Ebisuya M, Yamamoto T, Nakajima M, Nishida E (2008) Ripples from
neighbouring transcription. Nat Cell Biol 10: 1023–1024.
16. Gupta MP, Gupta M, Zak R, Sukhatme VP (1991) Egr-1, a serum-inducible
zinc finger protein, regulates transcription of the rat cardiac alpha-myosin heavy
chain gene. J Biol Chem 266: 12813–12816.
17. Zhao Y, Samal E, Srivastava D (2005) Serum response factor regulates a muscle-
specific microRNA that targets Hand2 during cardiogenesis. Nature 436:
214–220.
18. Kwon C, Han Z, Olson EN, Srivastava D (2005) MicroRNA1 influences cardiac
differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci
USA 102: 18986–18991.
19. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, et al. (2007)
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice
lacking miRNA-1-2. Cell 129: 303–317.
20. Ivey KN, Muth A, Arnold J, King FW, Yeh R-F, et al. (2008) MicroRNA
regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem
Cell 2: 219–229.
21. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, et al. (2006) The role of
microRNA-1 and microRNA-133 in skeletal muscle proliferation and differen-
tiation. Nat Genet 38: 228–233.
22. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF (2006)
Myogenic factors that regulate expression of muscle-specific microRNAs. Proc
Natl Acad Sci U S A 103: 8721–8726.
23. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, et al. (2007) MicroRNA-
133 controls cardiac hypertrophy. Nat Med 13: 613–618.
24. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, et al. (2008)
microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth
muscle gene expression in the heart. Genes Dev 22: 3242–3254.
25. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, et al. (2007) Control of
stress-dependent cardiac growth and gene expression by a microRNA. Science
316: 575–579.
26. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, et al. (2009) miR-
133 and miR-30 regulate connective tissue growth factor: implications for a role
of microRNAs in myocardial matrix remodeling. Circ Res 104: 170–178.
27. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, et al. (2009)
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.
J Clin Invest 119: 2772–2786.
28. Yan D, Dong XD, Chen X, Wang L, Lu C, et al. (2009) MicroRNA-1/206
targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284:
29596–29604.
29. Huang TH, Zhu MJ, Li XY, Zhao SH (2008) Discovery of porcine microRNAs
and profiling from skeletal muscle tissues during development. PLoS One 3:
e3225.
30. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. (2006) A
signature pattern of stress-responsive microRNAs that can evoke cardiac
hypertrophy and heart failure. Proc Natl Acad Sci U S A 103: 18255–18260.
31. Wang D, Lu M, Miao J, Li T, Wang E, et al. (2009) Cepred: predicting the co-
expression patterns of the human intronic microRNAs with their host genes.
PLoS One 4: e4421.
32. Kloosterman WP, Steiner FA, Berezikov E, de Bruijn E, van de Belt J, et al.
(2006) Cloning and expression of new microRNAs from zebrafish. Nucleic Acids
Res 34: 2558–2569.
33. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A
mammalian microRNA expression atlas based on small RNA library
sequencing. Cell 129: 1401–1414.
34. Liang Y, Ridzon D, Wong L, Chen C (2007) Characterization of microRNA
expression profiles in normal human tissues. BMC Genomics 8: 166.
35. Reddy AM, Zheng Y, Jagadeeswaran G, Macmil SL, Graham WB, et al. (2009)
Cloning, characterization and expression analysis of porcine microRNAs. BMC
Genomics 10: 65.
36. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, et al. (2009) A family
of microRNAs encoded by myosin genes governs myosin expression and muscle
performance. Dev Cell 17: 662–673.
37. Bell ML, Buvoli M, Leinwand LA (2010) Uncoupling of Expression of an
Intronic microRNA and its Myosin Host Gene by Exon Skipping. Mol Cell Biol
30: 1937–1945.
38. Sluijter JP, van Mil A, van Vliet P, Metz CH, Liu J, et al. (2010) MicroRNA-1
and -499 Regulate Differentiation and Proliferation in Human-Derived
Cardiomyocyte Progenitor Cells. Arterioscler Thromb Vasc Biol 30: 859–868.
39. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, et al.
(2009) Reciprocal regulation of myocardial microRNAs and messenger RNA in
human cardiomyopathy and reversal of the microRNA signature by biome-
chanical support. Circulation 119: 1263–1271.
40. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, et al. (2007) Altered microRNA
expression in human heart disease. Physiol Genomics 31: 367–373.
41. Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volinia S, et al. (2009)
Unique microRNA profile in end-stage heart failure indicates alterations in
specific cardiovascular signaling networks. J Biol Chem 284: 27487–27499.
42. Lyons GE, Schiaffino S, Sassoon D, Barton P, Buckingham M (1990)
Developmental regulation of myosin gene expression in mouse cardiac muscle.
J Cell Biol 111: 2427–2436.
43. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, et al. (1991) Tissue-
specific regulation of the alpha-myosin heavy chain gene promoter in transgenic
mice. J Biol Chem 266: 24613–24620.
44. Molkentin JD, Robbins J (2009) With great power comes great responsibility:
using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell
Cardiol 46: 130–136.
45. Hagiwara N, Yeh M, Liu A (2007) Sox6 is required for normal fiber type
differentiation of fetal skeletal muscle in mice. Dev Dyn 236: 2062–2076.
46. McCarthy JJ, Esser KA, Peterson CA, Dupont-Versteegden EE (2009) Evidence
of MyomiR network regulation of beta-myosin heavy chain gene expression
during skeletal muscle atrophy. Physiol Genomics 39: 219–226.
47. Komuro I, Kurabayashi M, Takaku F, Yazaki Y (1988) Expression of cellular
oncogenes in the myocardium during the developmental stage and pressure-
overloaded hypertrophy of the rat heart. Circ Res 62: 1075–1079.
48. Rozich JD, Barnes MA, Schmid PG, Zile MR, McDermott PJ, et al. (1995) Load
effects on gene expression during cardiac hypertrophy. J Mol Cell Cardiol 27:
485–499.
49. Saadane N, Alpert L, Chalifour LE (2000) Altered molecular response to
adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice.
Am J Physiol Heart Circ Physiol 278: H796–805.
50. Buitrago M, Lorenz K, Maass AH, Oberdorf-Maass S, Keller U, et al. (2005)
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac
hypertrophy. Nat Med 11: 837–844.
51. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, et al. (2005)
Temporally controlled onset of dilated cardiomyopathy through disruption of
the SRF gene in adult heart. Circulation 112: 2930–2939.
52. Liu L, Tsai JC, Aird WC (2000) Egr-1 gene is induced by the systemic
administration of the vascular endothelial growth factor and the epidermal
growth factor. Blood 96: 1772–1781.
53. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, et al. (2009)
MicroRNA-133a protects against myocardial fibrosis and modulates electrical
repolarization without affecting hypertrophy in pressure-overloaded adult
hearts. Circ Res 106: 166–175.
54. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. (2004) Human
MicroRNA targets. PLoS Biol 2: e363.
55. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
56. Wang X, El Naqa IM (2008) Prediction of both conserved and nonconserved
microRNA targets in animals. Bioinformatics 24: 325–332.
miR-499 Stress Response
PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e1948157. Rottman JN, Ni G, Brown M (2007) Echocardiographic evaluation of
ventricular function in mice. Echocardiography 24: 83–89.
58. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, et al. (2004) Mouse
cardiac surgery: comprehensive techniques for the generation of mouse models
of human diseases and their application for genomic studies. Physiol Genomics
16: 349–360.
59. Sharpe J, Ahlgren U, Perry P, Hill B, Ross A, et al. (2002) Optical projection
tomography as a tool for 3D microscopy and gene expression studies. Science
296: 541–545.
60. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
61. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment
tools: paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res 37: 1–13.
miR-499 Stress Response
PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e19481